April 2026
Galenica Group
Sales growth supported by acquisition of Labor Team
+7.3%
1'410
+4.3%
1'314
+11.6%
1'065
1'110
04/2025572
638
04/2026Galenica Group Products & Care Logistics & IT
Galenica Group
Sales growth supported by both segments
Net sales (in million CHF) | 2026 | 2025 | change |
Pharmacies Omni-Channel | 495.5 | 463.7 | +6.9% |
Products & Brands | 62.8 | 72.1 | -12.9% |
Services & Production | 41.9 | 38.4 | +9.1% |
Diagnostics | 40.8 | 0.0 | |
Products & Care | 637.7 | 571.6 | +11.6% |
Wholesale | 1'085.1 | 1'039.6 | +4.4% |
Logistics & IT Services | 25.9 | 26.3 | -1.4% |
Logistics & IT | 1'110.2 | 1'064.8 | +4.3% |
Galenica Group | 1'409.7 | 1'314.2 +7.3% |
Pharmacies Omni-Channel
Growth driven by prescription medicines and acquisitions
Net sales (in million CHF)464
+6.9%
496
Expansion impact1 of +2.9% due to acquisition of majority stake in puravita, portfolio of local pharmacies expanded by 3 locations
Generics substitution rate remains with 79.6% at high level (78.1% at Dec 2025).
04/2025 04/2026
1) The effect of net expansion is calculated only including point of sales without a full year period comparison (acquisitions, openings and closure of pharmacies)
Products & Brands
Growth dampend by bridging stock sales in prior year
Net sales (in million CHF)International 7257
53
10
15
-12.9%
63
-29.8%
-8.6%
Swiss market:
− Growth of CH market sales1 -2.2%
− Market share1 of 10.8%
04/2025 04/2026
1) Product sales to end customers of Verfora, Spagyros and Padma products (like-for-like, streetprices), IQVIA PharmaTrend for pharmacies and drugstores in Switzerland, Consumer Health market YTD April 2026
Services & Production
Strong sales growth in homecare business
Net sales (in million CHF)+9.1%
38
42
04/2025 04/2026
Consistent, strong growth with services for homecare organizations and nursing homes
Wholesale
Further market share gains in pharmacies segments
Net sales (in million CHF)PhysiciansPharmacies
63
62
676
716
302
306
+4.4%
1,040 1,085
04/2025 04/2026
+1.5%
+6.0%
+0.6%
Logistics & IT Services
Stable development with Prewholesale and IT services
Net sales (in million CHF)-1.4%
26 26
04/2025 04/2026
Swiss pharmaceutical market
in million CHF
760
740
720
700
680
660
640
620
600
580
560
540
520
500
Jan Feb Mrz Apr Mai Jun Jul Aug Sep Okt Nov Dez
2024 2025 2026Total market growth
CHF 2,686.9 million (+4.1%)
66.9 million packs (-1.4%)
CHF 647.4 million (+1.8%)
5.2 million packs (+0.8%)
24.1%
DrugstoresCHF 20.9 million (-2.3%)
2.0 million packs (-4.0%)
0.8%
26.5%
43.4%
Local PharmaciesCHF 1,167.1 million (+5.3%)
43.9 million packs (-1.6%)
PhysiciansCHF 712.5 million (+3.2%)
15.2 million packs (-0.7%)
5.2%
Mail-order PharmaciesCHF 138.8 million (+12.4%)
0.5 million packs (-8.4%)
Consumer healthcare market April 2026
2.9%
12.4%
18.1%
66.6%
Total market
CHF 871.2 million
+0.1%
Personal care
-1.4%
Patient care+2.3%
Nutrition+1.8%
Non-medication segment
+0.2%Source: IQVIA PharmaTrend for pharmacies and drugstores in Switzerland, streetprices
© IQVIA - Consumer Health market April 2026
Disclaimer
Disclaimer Galenica
Certain statements, beliefs and opinions in this presentation are forward-looking, which reflect the Company's or, as appropriate, the Company's directors' current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward-looking statements contained in this presentation regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward- looking statements in this presentation as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its of their parent or subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this presentation or the actual occurrence of the forecasted develop-ments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this presentation.
Disclaimer IQVIA © 2026, IQVIA AG
All rights reserved. The information may not be duplicated, stored, processed further, nor be made accessible in whole or in part to any third party without prior express and valid written permission of IQVIA AG. Terms used in connection with data/figures such as "patient", "doctor", "medical practice", "prescriber", or "pharmacy" do not designate any personal data but exclusively anonymous information (according to applicable, valid data protection laws).
IQVIA utilizes highly sophisticated technologies and methods in order to ensure that all its Information Services meet the applicable data protection requirements, regardless of the way data are combined.